Technology
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
PhaseV will analyse NeuroSense’s Phase II ALS trial data, and results from these will inform Phase III trial design, enrolment, and cost-effectiveness.
PhaseV will analyse NeuroSense’s Phase II ALS trial data, and results from these will inform Phase III trial design, enrolment, and cost-effectiveness.